Results 71 to 80 of about 482,699 (357)
Cancer immunotherapy as a new treatment option [PDF]
, 2019 Cancer can coaptate the immune control of the immune system (IS), evade immunity and its destruction. So, could we say openly that immunotherapy is a viable treatment option for patients with advanced cancer?
Alonso-Ortiz, Antonio +2 more
core
Breast Cancer Research, 2003 The use of appropriate mouse models in tumor immunotherapy is a crucial part of preclinical studies; indeed, without convincing 'mouse data', clinical studies usually do not ensue. However, there are problems in extrapolating from the mouse to the human; these will be separately considered for antibody-mediated and cell-mediated immunotherapy.
openaire +2 more sources
Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors
Molecular Oncology, EarlyView.Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi +6 more
wiley +1 more source
Cancer immunotherapy by immunosuppression [PDF]
Theoretical Biology and Medical Modelling, 2010 We have previously suggested that the stimulatory effect of a weak immune reaction on tumor growth may be necessary for the growth of incipient tumors. In the present paper, we enlarge upon and extend that idea by collecting evidence in the literature bearing upon the new hypothesis that a growing cancer, whether in man or mouse, is throughout its ...
Richmond T. Prehn, Liisa M Prehn
openaire +3 more sources
Molecular Oncology, EarlyView.The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld +7 more
wiley +1 more source
Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy [PDF]
, 2018 Breast cancer patients who initially respond to cancer therapies often succumb to distant recurrence of the disease. It is not clear why people with the same type of breast cancer respond to treatments differently; some escape from dormancy and relapse ...
Manjili, Masoud H.
core +1 more source
Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance
Molecular Oncology, EarlyView.In this research, we analyzed the relationship between gut microbiota and tumor. We discovered that both subcutaneous and metastatic tumors would alter the composition and metabolic function of gut microbiota. Meanwhile, fecal microbiota transplantation also indicated the anti‐tumor role of the gut microbiota, revealing the crosstalk between tumor and ...
Siyuan Zhang +8 more
wiley +1 more source
Biochemistry and Biophysics Reports, 2016 Purpose: The clinical efficacy of cancer peptide vaccine therapy is insufficient. To enhance the anti-tumor effect of peptide vaccine therapy, we combined this therapy with an anti-CD4 mAb (GK1.5), which is known to deplete CD4+ cells, including ...
Norihiro Fujinami +8 more
doaj +1 more source
A stochastic individual-based model for immunotherapy of cancer [PDF]
Scientific Reports, 6, 24169 (2016), 2015 We propose an extension of a standard stochastic individual-based model in population dynamics which broadens the range of biological applications. Our primary motivation is modelling of immunotherapy of malignant tumours. In this context the different actors, T-cells, cytokines or cancer cells, are modelled as single particles (individuals) in the ...
arxiv +1 more source
Molecular Oncology, EarlyView.This study simultaneously investigated circulating tumor cells (CTCs) and exosomes from small‐cell lung cancer (SCLC) patients. The elevated expression of JUNB and CXCR4 in CTCs was a poor prognostic factor for SCLC patients, whereas exosomal overexpression of these biomarkers revealed a high discrimination ability of patients from healthy individuals,
Dimitrios Papakonstantinou +13 more
wiley +1 more source